Global Space Biology Market Expected to Grow 30% Annually, Reaching ~$1.2 Billion by 2027 – DeciBio Consulting Market Report

ANGELS–(BUSINESS WIRE)–DeciBio Consulting LLC’s latest market report, “DeciBio Space Biology Market Report 2022states that the global space biology market – driven by steady growth in academia and accelerating growth in biopharma and CROs, particularly in clinical trials – is expected to reach $1.2 billion. here 2027.

This report summarizes the current and future (2022-2027) landscape of the space biology products and services market, with a focus on space and multiplex chemistries and methods. Informed by primary and secondary research, DeciBio’s proprietary databases and tools, and the expertise of DeciBio’s consultants, this report provides quantitative and qualitative assessments of key market segments (e.g. technology, customer type, application, plex level). Additionally, the report details market drivers (e.g. increased adoption in certain customer segments), moderators (e.g. high cost of instruments and reagents), trends (e.g. interest in combine spatial transcriptomics with proteomics) and detailed profiles of key players. .

Spatial biology can be defined as the analysis of one or more target analytes in a tissue in a spatial context (i.e. the expression of the marker in the context of its location in the tissue and/or d ‘other markers), and is mainly focused Analysis of biomarkers. Academia has been the largest customer segment of space biology analysis to date, however, its use in biopharmaceutical translational research and clinical trials is increasing as preliminary studies yield promising results and as technologies and analytical pipelines become more accessible and validated. Continued advancements in scalability, standardization, and clinical utility are expected to drive growth at all stages of R&D.

Report Methodology/Scope:

Learn more about DeciBio’s Space Biology Market Report, First Edition: 4th Quarter 2022

https://www.decibio.com/market-reports/spatial-biology-market

Space biology companies cited:

• Abcam

• Acuity Spatial Genomics

• Advanced cell diagnostics (Bio-Techne)

• Akoya Biosciences

• AmberGen

• Bethyl Laboratories

• BioCare Medical

• bioSyntagma

• Canopy Biosciences

• Cell IDx (Leica Biosystems)

• Cell Carta

• Cellecta

• Cerba Research

• Crown Bioscience

• Cytiva

• Enzo life sciences

• Flagship Biosciences

• 10x Genomics

• Individual

• ionpath

• LabCorp

• Leica Biosystems

• Leica Microsystems

• Lunaphore

• Miltenyi Biotec

• Nanochord

• NeoGenomics

• United Kingdom

• Q² Solutions

• RareCyte

• Rebus Biosystems

• Solving Biosciences

• Roche Diagnostics

• Spatial genomics

• Standard organic tools

• Syncell

• Ultiview

• Vector labs

• Veracyte

• Visikol

• Vizgen

• Other

Analysis of the space biology market:

Market factors

Proactive data generation, the rise of immuno-oncology, and improvements (in capabilities, ease of access, and flexibility of platforms and chemistries) will drive the adoption and use of space biology and will drive the growth of the market. Important technical and data-driven insights will continue to emerge and drive market value in the space biology industry as analytical capabilities are enhanced by emerging image analysis algorithms based on AI and digital pathology. The sheer interest – and funding – in space technologies and companies will drive general industry interest in bringing these new tools to market.

Market Moderators

There are still barriers to market entry and development in space biology. Sufficient prospective primary results in clinical data for spatial signatures are necessary for tangible success in clinical adoption. Additionally, to ensure market success, clinics must develop regulatory and payment policies and data platforms that support high-plex tissue analysis. Cost is also a barrier to implementation due to high cost per assay (up to $5000 per slide) and bioinformatics costs (e.g. up to additional $5000 per slide or more for multiple analyses). Finally, empirical data is imperative to assuage scalability issues, as throughput is still limited (e.g., ~20 slides per day for a 3-6-plex mIF slide, versus as low as 1 slide per day for 20 +plex). As clinical infrastructure evolves and spatial signatures gain traction, there is a wide window of opportunity and market growth.

About DeciBio:

DeciBio Consulting (www.decibio.com) is the leading strategy consulting, market intelligence and SaaS firm dedicated to accelerating the adoption and impact of technologies enabling precision medicine.

Based in Los Angeles, California, DeciBio serves a global base of clients and customers, ranging from startups to Fortune 500 healthcare companies. DeciBio offers consulting services for growth planning, market assessment and opportunities, product and portfolio strategy, customer feedback, technology assessment and business due diligence.